SG11201811479RA - An antibacterial composition and a method of treating staphylococcal infections with the antibacterial composition - Google Patents
An antibacterial composition and a method of treating staphylococcal infections with the antibacterial compositionInfo
- Publication number
- SG11201811479RA SG11201811479RA SG11201811479RA SG11201811479RA SG11201811479RA SG 11201811479R A SG11201811479R A SG 11201811479RA SG 11201811479R A SG11201811479R A SG 11201811479RA SG 11201811479R A SG11201811479R A SG 11201811479RA SG 11201811479R A SG11201811479R A SG 11201811479RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- dong
- antibacterial composition
- songpa
- seoul
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Materials For Medical Uses (AREA)
- Peptides Or Proteins (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11111111011110111010101111101011111011101110111011101110111011111101111011111 International Bureau .. .... ..Yd j .n. ..1:2 (10) International Publication Number (43) International Publication Date WO 2017/122111 Al 20 July 2017 (20.07.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 38/16 (2006.01) A61K 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/1B2017/050087 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, 9 January 2017 (09.01.2017) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (25) Filing Language: English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (26) Publication Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (30) Priority Data: ZA, ZM, ZW. 62/277,506 12 January 2016 (12.01.2016) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: INTRON BIOTECHNOLOGY, INC. kind of regional protection available): ARIPO (BW, GH, [KR/KR]; #1007, JungAng Induspia V, 138-6 Sangdae- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, won-Dong, Jungwon-Gu, Seongnam-Si, Gyeonggi-do, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 462-120 (KR). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (72) Inventors: YOON, Seong Jun; #301 Shinhan Apt., DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Galak2-Dong, Songpa-Ku, Seoul, 138-807 (KR). JUN, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Soo Youn; #301 Shinhan Apt., Galak2-Dong, Songpa-Ku, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Seoul, 138-807 (KR). JUNG, Gi Mo; #301 Shinhan Apt., GW, KM, ML, MR, NE, SN, TD, TG). Galak2-Dong, Songpa-Ku, Seoul, 138-807 (KR). KANG, Published: — with international search report (Art. 21(3)) Sang Hyeon; #507-310 Jugong-5-danzi Apt., 27, Jam- sil-Dong, Songpa-Ku, Seoul, 138-225 (KR). — with sequence listing part of description (Rule 5.2(a)) (74) Agent: MIN, H. Timothy; SIMI, 1 Broadway, 14th Floor, Cambridge, Massachusetts 02142 (US). OF TREATING STAPHYLOCOCCAL INFECTIONS (54) Title: AN ANTIBACTERIAL COMPOSITION AND A METHOD WITH THE ANTIBACTERIAL COMPOSITION Figure 1 Staphylococcus arlettae Strain: KTC VMS iATCC 439571 (A) (B) reduction assay (0.5 Kim!) Spot-on-lawn assay Turbidity ..,,,,,. ..=ilii 1-1 1-1 1-1 1-1 0 N 1 , 1 ei ,-1 TOD = 13.0 IN 1-1 0 (57) : A method of treating staphylococcal infections includes administering to a subject an effective amount of an antibac - \" terial composition having a broad bactericidal activity. The antibacterial composition includes a first antibacterial protein consisting C of the amino acid sequence as set forth in SEQ. ID . NO: 1 and/or a second antibacterial protein consisting of the amino acid se - .• quence as set forth in SEQ. ID. NO: 2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277506P | 2016-01-12 | 2016-01-12 | |
| PCT/IB2017/050087 WO2017122111A1 (en) | 2016-01-12 | 2017-01-09 | An antibacterial composition and a method of treating staphylococcal infections with the antibacterial composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811479RA true SG11201811479RA (en) | 2019-01-30 |
Family
ID=59310874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811479RA SG11201811479RA (en) | 2016-01-12 | 2017-01-09 | An antibacterial composition and a method of treating staphylococcal infections with the antibacterial composition |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11229677B2 (en) |
| EP (1) | EP3402506A4 (en) |
| JP (1) | JP7085483B2 (en) |
| CN (1) | CN109414478B (en) |
| AU (1) | AU2017208114B2 (en) |
| BR (1) | BR112018014175A2 (en) |
| CA (1) | CA3010564C (en) |
| MX (1) | MX2018008545A (en) |
| RU (2) | RU2729934C2 (en) |
| SG (1) | SG11201811479RA (en) |
| UA (1) | UA126022C2 (en) |
| WO (1) | WO2017122111A1 (en) |
| ZA (1) | ZA201804013B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110734474B (en) * | 2019-11-29 | 2021-10-19 | 中山大学 | Screening method and application of antibacterial peptide |
| CN111235119B (en) * | 2020-03-05 | 2021-11-23 | 苏州十一方生物科技有限公司 | Preparation and application of fusion antibacterial protein |
| CN112402591B (en) * | 2020-11-23 | 2022-12-16 | 中国农业科学院饲料研究所 | Application of defensin DLP4 in treatment of exudative dermatitis of piglets |
| KR20240015753A (en) * | 2022-07-26 | 2024-02-06 | 주식회사 인트론바이오테크놀로지 | Antibacterial Protein Having Strong Lytic Activity to Staphylococci including Staphylococcus aureus |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9609743A (en) | 1995-07-27 | 1999-03-02 | Genentech Inc | Stable reconstituted formulation method for the preparation of a manufactured article formulation and use of the formation |
| IE20060488A1 (en) * | 2006-06-29 | 2008-01-09 | Teagasc Agric Food Dev Authori | Recombinant staphylococcal phage lysin as an antibacterial agent |
| KR100759988B1 (en) * | 2006-08-04 | 2007-09-19 | 주식회사 인트론바이오테크놀로지 | Antimicrobial protein specific to staphylococcus aureus |
| KR100910961B1 (en) * | 2007-09-13 | 2009-08-05 | 주식회사 인트론바이오테크놀로지 | Bacteriophage or Lytic Protein Derived From the Bacteriophage Which Effective For Treatment of Staphylococcus aureus Biofilm |
| KR101016918B1 (en) | 2009-01-08 | 2011-02-25 | 주식회사 인트론바이오테크놀로지 | Novel Lysin Protein Having Broad Antibacterial Activity Specific to Bacteria |
| US8043613B2 (en) * | 2009-02-12 | 2011-10-25 | Intron Biotechnology, Inc. | Podoviriedae bacteriophage having killing activity specific to Staphylococcus aureus |
| US9603909B2 (en) | 2012-05-29 | 2017-03-28 | Intron Biotechnology, Inc. | Composition capable of improving stability of bacteriophage lysin proteins |
| CA3010565C (en) * | 2016-01-12 | 2024-05-14 | Intron Biotechnology, Inc. | Freeze-dried formulations of antibacterial protein |
-
2017
- 2017-01-09 CA CA3010564A patent/CA3010564C/en active Active
- 2017-01-09 UA UAA201813040A patent/UA126022C2/en unknown
- 2017-01-09 BR BR112018014175A patent/BR112018014175A2/en unknown
- 2017-01-09 SG SG11201811479RA patent/SG11201811479RA/en unknown
- 2017-01-09 RU RU2019136978A patent/RU2729934C2/en active
- 2017-01-09 EP EP17738258.7A patent/EP3402506A4/en active Pending
- 2017-01-09 US US16/300,566 patent/US11229677B2/en active Active
- 2017-01-09 RU RU2018124798A patent/RU2707738C1/en active
- 2017-01-09 AU AU2017208114A patent/AU2017208114B2/en active Active
- 2017-01-09 JP JP2018536456A patent/JP7085483B2/en active Active
- 2017-01-09 WO PCT/IB2017/050087 patent/WO2017122111A1/en active Application Filing
- 2017-01-09 CN CN201780006444.8A patent/CN109414478B/en active Active
- 2017-01-09 MX MX2018008545A patent/MX2018008545A/en unknown
-
2018
- 2018-06-15 ZA ZA2018/04013A patent/ZA201804013B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3402506A1 (en) | 2018-11-21 |
| JP7085483B2 (en) | 2022-06-16 |
| US20190282657A1 (en) | 2019-09-19 |
| ZA201804013B (en) | 2019-07-31 |
| BR112018014175A2 (en) | 2018-12-26 |
| CA3010564A1 (en) | 2017-07-20 |
| RU2019136978A3 (en) | 2020-04-02 |
| MX2018008545A (en) | 2018-12-19 |
| RU2707738C1 (en) | 2019-11-29 |
| EP3402506A4 (en) | 2019-09-04 |
| UA126022C2 (en) | 2022-08-03 |
| AU2017208114A1 (en) | 2018-07-26 |
| RU2019136978A (en) | 2019-12-19 |
| CN109414478A (en) | 2019-03-01 |
| AU2017208114B2 (en) | 2023-04-13 |
| US11229677B2 (en) | 2022-01-25 |
| CA3010564C (en) | 2024-01-30 |
| JP2019503379A (en) | 2019-02-07 |
| CN109414478B (en) | 2022-08-23 |
| WO2017122111A1 (en) | 2017-07-20 |
| KR20180114010A (en) | 2018-10-17 |
| RU2729934C2 (en) | 2020-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201805162VA (en) | Plasmid constructs for heterologous protein expression and methods of use | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201408174UA (en) | Antibody formulation | |
| SG11201804729RA (en) | Methods and compositions for treating a serpinc1-associated disorder | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201811479RA (en) | An antibacterial composition and a method of treating staphylococcal infections with the antibacterial composition | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201805579SA (en) | Recombinant igg fc multimers | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201810561YA (en) | Liquid neurotoxin formulation stabilized with tryptophan or tyrosine | |
| SG11201901374WA (en) | Antibiotic compounds | |
| SG11201805755SA (en) | Methods of administering hepcidin | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201809100QA (en) | Use of gram negative species to treat atopic dermatitis |